Vaccines offer strong protection against death from COVID-19 Delta variant
The research, involving the University of Strathclyde, has found that the Pfizer-BioNTech vaccine is 90 per cent effective and the Oxford-AstraZeneca vaccine 91 per cent effective in preventing deaths in people who have been double vaccinated, but who have tested positive for coronavirus in the community
Vaccination is over 90 per cent effective at preventing deaths from the Delta variant of COVID-19, according to the first country-level data on mortality.
The research, involving the University of Strathclyde, has found that the Pfizer-BioNTech vaccine is 90 per cent effective and the Oxford-AstraZeneca vaccine 91 per cent effective in preventing deaths in people who have been double vaccinated, but who have tested positive for coronavirus in the community.
The study, using data from the Scotland-wide EAVE II COVID-19 surveillance platform, is the first to show across an entire country how effective vaccines are at preventing death from the Delta variant, which is now the dominant form of COVID-19 in the UK and many other countries.
Researchers analysed data from 5.4 million people in Scotland between 1st April and 27th September, 2021. During this period, 115,000 people tested positive for COVID-19 through a PCR test conducted in the community, rather than in hospital, and there were 201 deaths recorded due to the virus.
The Moderna vaccine is also available in Scotland and no deaths have been recorded in those who have been double vaccinated with it. Consequently, it has not been possible to estimate its effectiveness in preventing death, the researchers said.
The researchers defined death from COVID-19 as anyone who died within 28 days of a positive PCR test, or with COVID-19 recorded as a cause of death on their death certificate.
The research team, from Strathclyde, the University of Edinburgh and Public Health Scotland, analysed a dataset as part of the EAVE II project, which uses anonymised linked patient data to track the pandemic and the vaccine roll out in real time.
The results are published as a letter in the New England Journal of Medicine.
Professor Chris Robertson, Strathclyde’s Department of Mathematics and Statistics, said, “This study shows the value of carrying out analyses of routine healthcare data available in near real-time.
“Our findings are encouraging in showing that the vaccine remains an effective measure in protecting both ourselves and others from death from the most dominant variant of COVID-19. It is important to validate these early results in other settings and with a longer follow-up study.”
The researchers say that to increase confidence in these early findings, the research needs to be repeated in other countries and settings, and with longer follow-up time after full vaccination.
The team says that because of the observational nature of the study, data about vaccine effectiveness should be interpreted with caution and it is not possible to make a direct comparison between both vaccines.
The study was funded by the Medical Research Council, UK Research and Innovation Industrial Strategy Challenge Fund, the National Institute for Health Research and Health Data Research UK (HDR UK), and was supported by the Scottish Government.
Additional support was provided through the Scottish Government Director-General Health and Social Care, and the UKRI COVID-19 National Core Studies Data and Connectivity programme led by HDR UK.